Clinical data | |
---|---|
Trade names | Erispan (JP, TW) |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral (tablets) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.292.343 ![]() |
Chemical and physical data | |
Formula | C16H12ClFN2O |
Molar mass | 302.7 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Fludiazepam,[1] marketed under the brand name Erispan (エリスパン)[2][3] is a potent benzodiazepine and 2ʹ-fluoro derivative of diazepam,[4] originally developed by Hoffman-La Roche in the 1960s.[5] It is marketed in Japan and Taiwan.[citation needed] It exerts its pharmacological properties via enhancement of GABAergic inhibition.[6] Fludiazepam has 4 times more binding affinity for benzodiazepine receptors than diazepam.[7] It possesses anxiolytic,[8][9][10] anticonvulsant, sedative, hypnotic and skeletal muscle relaxant properties.[11] Fludiazepam has been used recreationally.[12]
5-HT1AR agonists | |
---|---|
GABAAR PAMs |
|
Gabapentinoids (α2δ VDCC blockers) | |
Antidepressants |
|
Sympatholytics (Antiadrenergics) |
|
Others | |
|